期刊文献+

生物药物分析方法验证体系的研究

Study on Validation System for Biopharmaceutical Analytical Methods
下载PDF
导出
摘要 目的:探讨生物药物分析方法验证中存在的问题及改良策略。方法:分析国内外对于生物药物分析方法验证的理念、特点及研究进展,将质量源于设计的理念同传统方法验证理念进行比较研究。结果与结论:将指标化、终点化控制的传统验证体系改良为可视化、可溯源、立体化过程控制的方法验证系统。将方法建立及验证工作有机融合一体,为高质量数据提供保障。这个体系不但可有效整理记录方法建立及验证过程,利于分析方法转移过程中有效信息的传递,也有利于生物药物分析方法的评价和研究。 Objective: To investigate drawbacks and measures for improving of validation of biopharmaceutical analytical methods. Methods: The concept, characteristics and research progress of validation of analytical methods in worldwide biopharmaceutical researches were studied, and the novel concept of 'quality by design' was compared with the traditional concept on method validation. Results and Conclusion: The traditional indexing, end point-controlled method validation system was changed into the novel method validation system with visualization, tracking, and three-dimensional process. The novel system combined establishment with validation of analytical methods, and provided data of high quality. Moreover, this system could effectively record the process of method establishment and validation which was helpful for both information transmission in analysis method transference and evaluation of biopharmaceutical analytical methods.
出处 《中国药事》 CAS 2015年第3期273-276,共4页 Chinese Pharmaceutical Affairs
基金 国家科技重大专项(编号2012ZX10001008-015 2012ZX09101313) 国家科技支撑计划(编号2012AA02A701) 河北省自然科学基金项目(编号2009000290)
关键词 生物药物分析方法 方法验证 质量源于设计 体系改进 方法转移 biopharmaceutical analytical methods validation of methods quality by design (QbD) systemimprovement method transference
  • 相关文献

参考文献11

二级参考文献34

  • 1竟永华,郭剑非,李行.美国药品风险管理指南与案例分析[J].中国药物警戒,2005,2(4):193-196. 被引量:15
  • 2Bemelmans MH, Van Tits LJ, Burman WA. Tumor necrosis factor: function, release and clearance [J]. Crit Rev Immunol, 1996, 16 (1): 1-11.
  • 3Bradley JR. TNF-mediated inflammatory disease [J]. J Pathol, 2008, 214 (2): 149-160.
  • 4Sacca R, Cuff CA, Lesslauer W, et al. Differential activities of secreted lymphotoxin-alpha3 and membrane lymphotoxin-alphalbeta2 in lymphotoxin-induced inflammation: critical role of TNF receptor 1 signaling [J]. J Immunol, 1995, 160 (1): 485-491.
  • 5Zhou H. Clinical pharmacokinetics of etanercept: a fully humanized soluble recombinant tumor necrosis factor receptor fusion protein [J]. J Clin Pharmacol, 2005, 45 (5): 490-497.
  • 6Feldmann M, Maini RN. Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned [J]. Annu Rev Immunol, 2001, 19: 163-196.
  • 7Aggarwal S. What's fueling the biotech engine-2007 [J]. Nat Biotech, 2008, 26 ( 11 ) : 1227-1233.
  • 8Chen C. Chanllenges and opportunities of monoclonal antibody manufacturing in China [J ]. Trends Bio/Pharmaceutical Industry, 2009, 5 (3): 28-33.
  • 9鞠佃文.中国抗体药物的研发.Trends in Bio/pharmaceutical Industry,2009,5(3):34-40.
  • 10Griffiths S. Betting on biogenerics [J]. Nature Rev Drug Discov, 2004, 3 (3): 197-198.

共引文献80

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部